tetano
Editor, Senior Moderator
Methods Mol Biol
. 2022;2410:149-175.
doi: 10.1007/978-1-0716-1884-4_7.
Vaccines Targeting Numerous Coronavirus Antigens, Ensuring Broader Global Population Coverage: Multi-epitope and Multi-patch Vaccines
Sukrit Srivastava[SUP] 1 [/SUP], Spyros D Chatziefthymiou[SUP] 2 3 [/SUP], Michael Kolbe[SUP] 4 5 [/SUP]
Affiliations
Abstract
Coronaviruses are causative agents of different zoonosis including SARS, MERS, or COVID-19 in humans. The high transmission rate of coronaviruses, the time-consuming development of efficient anti-infectives and vaccines, the possible evolutionary adaptation of the virus to conventional vaccines, and the challenge to cover broad human population worldwide are the major reasons that made it challenging to avoid coronaviruses outbreaks. Although, a plethora of different approaches are being followed to design and develop vaccines against coronaviruses, most of them target subunits, full-length single, or only a very limited number of proteins. Vaccine targeting multiple proteins or even the entire proteome of the coronavirus is yet to come. In the present chapter, we will be discussing multi-epitope vaccine (MEV) and multi-patch vaccine (MPV) approaches to design and develop efficient and sustainably successful strategies against coronaviruses. MEV and MPV utilize highly conserved, potentially immunogenic epitopes and antigenic patches, respectively, and hence they have the potential to target large number of coronavirus proteins or even its entire proteome, allowing us to combat the challenge of its evolutionary adaptation. In addition, the large number of human leukocyte antigen (HLA) alleles targeted by the chosen specific epitopes enables MEV and MPV to cover broader global population.
Keywords: Ag-Patch (antigenic patch); COVID-19; Coronavirus; Epitopes; MERSSARS; Multi-epitope vaccine; Multi-patch vaccine; Reverse epitomics; SARS-CoV-2.
. 2022;2410:149-175.
doi: 10.1007/978-1-0716-1884-4_7.
Vaccines Targeting Numerous Coronavirus Antigens, Ensuring Broader Global Population Coverage: Multi-epitope and Multi-patch Vaccines
Sukrit Srivastava[SUP] 1 [/SUP], Spyros D Chatziefthymiou[SUP] 2 3 [/SUP], Michael Kolbe[SUP] 4 5 [/SUP]
Affiliations
- PMID: 34914046
- DOI: 10.1007/978-1-0716-1884-4_7
Abstract
Coronaviruses are causative agents of different zoonosis including SARS, MERS, or COVID-19 in humans. The high transmission rate of coronaviruses, the time-consuming development of efficient anti-infectives and vaccines, the possible evolutionary adaptation of the virus to conventional vaccines, and the challenge to cover broad human population worldwide are the major reasons that made it challenging to avoid coronaviruses outbreaks. Although, a plethora of different approaches are being followed to design and develop vaccines against coronaviruses, most of them target subunits, full-length single, or only a very limited number of proteins. Vaccine targeting multiple proteins or even the entire proteome of the coronavirus is yet to come. In the present chapter, we will be discussing multi-epitope vaccine (MEV) and multi-patch vaccine (MPV) approaches to design and develop efficient and sustainably successful strategies against coronaviruses. MEV and MPV utilize highly conserved, potentially immunogenic epitopes and antigenic patches, respectively, and hence they have the potential to target large number of coronavirus proteins or even its entire proteome, allowing us to combat the challenge of its evolutionary adaptation. In addition, the large number of human leukocyte antigen (HLA) alleles targeted by the chosen specific epitopes enables MEV and MPV to cover broader global population.
Keywords: Ag-Patch (antigenic patch); COVID-19; Coronavirus; Epitopes; MERSSARS; Multi-epitope vaccine; Multi-patch vaccine; Reverse epitomics; SARS-CoV-2.